Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com.

START WITH ONE - Glasgow SBS-IF Service and Adult Patient Selection, Initiation and Experience - Chaptered Video (11mins)

Watch this video featuring Phil Stevens and Rebecca Turner, to learn about the setting-up and impact of a Revestive®▼ (teduglutide) service for SBS-IF at the Glasgow Royal Infirmary. This video describes:

1.The Glasgow SBS-IF Service and the Impact of SBS-IF on Patients' Lives: Discusses the patient demographics, the challenges faced by patients with short bowel syndrome and intestinal failure, and the impact on their quality of life.

2.The Introduction and Impact of Revestive: Details how Revestive has been an exciting development in treatment, its benefits, and how it could help to transform patient care and clinical practice.

3. Patient Selection, Counselling, and Monitoring: Explains the importance of patient motivation, the counselling process, and the monitoring required for patients starting on Revestive, including a case study and the approach to patient management.

C-APROM/GB/REV/0305 Date of preparation March 2025